PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025
PAVmed (Nasdaq: PAVM), a diversified commercial-stage medical technology company, has scheduled a business update conference call and webcast for August 14, 2025, at 8:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PAVmed (Nasdaq: PAVM), a diversified commercial-stage medical technology company, has scheduled a business update conference call and webcast for August 14, 2025, at 8:30 AM ET. During the call, Chairman and CEO Dr. Lishan Aklog will discuss company operations and growth strategy, while President and CFO Dennis McGrath will present Q2 2025 financial results.
Investors can access the webcast through PAVmed's investor relations website. For telephone access, U.S. callers should dial 1-800-836-8184, while international callers can use 1-646-357-8785. A 30-day replay will be available on the company website following the call.
Details
News Market Reaction – PAVM
The recorded move for PAVM in the trading session of this news was +1.71%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast at 8:30 AM Eastern Time
The webcast will be available at the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone,
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.
For more and for more information about PAVmed, please visit pavmed.com.
For more information about Lucid Diagnostics, please visit luciddx.com.
For more information about Veris Health, please visit verishealth.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-to-hold-a-business-update-conference-call-and-webcast-on-august-14-2025-302517035.html
SOURCE PAVmed Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.